Lonapegsomatropin
Also known as: Lonapegsomatropin, lonapegsomatropin-tcgd, PEG-hGH prodrug, SKYTROFA, TransCon hGH
Source Lonapegsomatropin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lonapegsomatropin is a long‑acting, once‑weekly subcutaneous growth hormone prodrug approved for treatment of growth hormone deficiency in pediatric patients.
Mechanism of Action
Prodrug releases somatropin which binds GH receptors, stimulating IGF‑1 production and linear growth
Routes of Administration
Goals & Uses
- Normalization of IGF-1 levelsBiomarker / MetabolicHigh
- Adult growth hormone deficiency (investigational)EndocrinologyModerate
- Treatment of pediatric growth hormone deficiencyEndocrinology / GrowthHigh
- Improved treatment adherence via weekly dosingPatient Convenience / AdherenceHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Acute critical illnessCritical CareHigh
- Closed epiphyses (skeletal maturity)DevelopmentalModerate
- Closed epiphyses (for growth promotion indication)Pediatric / SkeletalModerate
- Hypersensitivity to somatropin or PEG componentsAllergy / ImmunologyHigh
- Diabetic retinopathyOphthalmologyModerate
- Prader-Willi syndrome with severe obesity or respiratory impairmentGenetic SyndromeHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Intracranial hypertension (benign)NeurologicalRare
- Joint pain (arthralgia)MusculoskeletalUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated IGF-1 levels (above normal range)Endocrine / MetabolicCommon
- Slipped capital femoral epiphysisMusculoskeletalRare
- HypothyroidismEndocrineUncommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Cytochrome P450 substrates (e.g., cyclosporine, sex hormones, anticonvulsants)Low
- Insulin and antidiabetic agentsModerate
- Oral estrogenLow
- Thyroid hormone replacementModerate
Population Constraints
- Adults (off-label use)AdultRelative
- AdultsAdult PopulationRelative
- Patients with diabetes mellitusMetabolicRelative
- Pediatric patients with confirmed growth hormone deficiencyIndicationAbsolute
- Pediatric patients <1 year or weighing <11.5 kgPediatricAbsolute
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionApprovedApproved: Pediatric growth hormone deficiencyEMA approval 2022
- United StatesApprovedApproved: Pediatric growth hormone deficiencyFDA approval 2021; marketed as Skytrofa
- United KingdomApprovedApproved: Pediatric growth hormone deficiencyMHRA approved following EMA decision; available in the UK market.
Approved by FDA (2021) as Skytrofa; EMA approval for pediatric GHD (2022).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lonapegsomatropin?
Lonapegsomatropin is a long‑acting, once‑weekly subcutaneous growth hormone prodrug approved for treatment of growth hormone deficiency in pediatric patients.
What is Lonapegsomatropin used for?
Lonapegsomatropin is educationally associated with: Normalization of IGF-1 levels, Adult growth hormone deficiency (investigational), Treatment of pediatric growth hormone deficiency, Improved treatment adherence via weekly dosing. Educational only — not medical advice.
How is Lonapegsomatropin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Lonapegsomatropin?
Reported adverse effects include: Edema, Hyperglycemia, Intracranial hypertension (benign), Joint pain (arthralgia), Injection site reactions, Headache, Elevated IGF-1 levels (above normal range), Slipped capital femoral epiphysis, Hypothyroidism. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lonapegsomatropin?
Recorded contraindications: Active malignancy, Acute critical illness, Closed epiphyses (skeletal maturity), Closed epiphyses (for growth promotion indication), Hypersensitivity to somatropin or PEG components, Diabetic retinopathy, Prader-Willi syndrome with severe obesity or respiratory impairment. Consult a qualified clinician before use.